Anixa Biosciences (NASDAQ:ANIX – Get Free Report) and OptiNose (NASDAQ:OPTN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Risk & Volatility
Anixa Biosciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.
Insider & Institutional Ownership
29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 2.3% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anixa Biosciences | $210,000.00 | 487.28 | -$9.81 million | ($0.39) | -8.15 |
| OptiNose | $70.99 million | 1.15 | -$35.48 million | ($0.28) | -1.94 |
Anixa Biosciences has higher earnings, but lower revenue than OptiNose. Anixa Biosciences is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Anixa Biosciences and OptiNose, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anixa Biosciences | 0 | 0 | 2 | 1 | 3.33 |
| OptiNose | 0 | 0 | 3 | 0 | 3.00 |
Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 167.30%. OptiNose has a consensus target price of $3.00, suggesting a potential upside of 452.49%. Given OptiNose’s higher probable upside, analysts plainly believe OptiNose is more favorable than Anixa Biosciences.
Profitability
This table compares Anixa Biosciences and OptiNose’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anixa Biosciences | N/A | -54.79% | -50.37% |
| OptiNose | -41.16% | N/A | -27.42% |
Summary
OptiNose beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
